Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib

Table 5

Multivariable analysis of factors associated with progression free survival and overall survival.

Prognostic factors	Progression free survival			Overall survival
	HR	95% CI	value	HR	95% CI	value
Pre-NLR (≤ 3.41 vs. >3.41)	1.200	0.760-1.895	0.433	1.408	0.862-2.299	0.171
Pre-PLR (≤ 205.63 vs. >205.63)	1.642	1.036-2.603	0.035	1.655	1.004-2.729	0.048
Post-NLR variation (decrease vs. rise)	1.772	1.268-2.477	0.001	2.047	1.404-2.984	0.001